Background: Dexamethasone or indomethacin predisposes very low birth weight (VLBW) neonates to spontaneous intestinal perforation (SIP). However, no study has specifically investigated the role of the concurrent use of indomethacin and dexamethasone in SIP.
Introduction
Spontaneous intestinal perforation (SIP) occurs in about 1-7% of very low birth weight (VLBW) neonates.
1,2 Not unexpectedly, its incidence is higher in the more immature patient population. 3 In the VLBW neonate, SIP is generally defined as a 5-10 mm perforation on the antimesenteric border of the distal ileum. 4, 5 It may occur as a single 'blow-out' lesion or present in the form of multiple perforations. 4, 5 Interestingly, in the near-term and term neonate SIP primarily occurs in the colon rather than in the ileum and carries a better prognosis. 6 In the VLBW neonate, SIP differs from necrotizing enterocolitis (NEC) by its clinical presentation and by the lack of widespread segmental bowel ischemia and coagulation necrosis. 1 Clinically, SIP usually presents during the first two postnatal weeks often with marked abdominal wall discoloration 5, 7, 8 and without significant physiologic deterioration. 9 Initial radiological findings characteristic for SIP consist of a gasless abdomen without pneumatosis intestinalis or portal venous air. 10 With progression of the condition, a pneumoperitoneum and/or persistent dilated bowel loops may then be detected. 1, 5, 10 Risk factors contributing to the development of SIP have been proposed but not proven and include umbilical arterial catheters, 4, 11 birth asphyxia, RDS, 12 bacterial infection of the gastrointestinal tract, 13 intestinal obstruction, 13 mechanical ventilation by face mask or nasal prongs, 14 cytomegalovirus infection, 14 congenital defects in the intestinal musculature, 14 low birth weight, 2,15 male gender, 2 twin gestation, 2 intrauterine cocaine exposure, 2 patent ductus arteriosus (PDA), 15, 16 systemic candidiasis, 17 postnatal corticosteroids, 14, 16 and postnatal indomethacin. 14, 16 Of the proposed risk factors, exposure to postnatal corticosteroids or indomethacin and low birth weight, umbilical arterial catheters and infection have been most frequently associated with the development of SIP. Most 2,16 -24 but not all 10, 25 studies have found an increased likelihood of SIP when dexamethasone or hydrocortisone is used early for the prevention of bronchopulmonary dysplasia (BPD) or prophylaxis for early adrenal insufficiency and arterial pressure support, respectively. Data on the association between postnatal indomethacin administration and SIP are more contradictory as some studies found no evidence for an increased risk of SIP with indomethacin exposure 5, 11, 15, [25] [26] [27] while others did find that indomethacin administration is associated with an increased risk of SIP. 1,2,8,16,22,28 -31 As for a potential association between SIP and the concomitant use of indomethacin and corticosteroids, available data suggest an increased risk for SIP in patients receiving both medications irrespective of the type of corticosteroid (dexamethasone or hydrocortisone) used. 19, 20, 22, 25 However, since in these studies SIP was only a secondary outcome measure, these studies were not designed to specifically test for the presence of this association. Here, we report the findings of our retrospective case-control study designed to specifically test the hypothesis that concurrent administration of early corticosteroids (low-dose dexamethasone for vasopressor-resistant hypotension) and indomethacin increases the risk of SIP.
Materials and Methods
This retrospective case-control study was conducted among preterm neonates with a birth weight of <1500 g born at the Women's and Children's Hospital of the Los Angeles County þ University of Southern California Medical Center and the Hospital of the Good Samaritan, Los Angeles, California between 1 January 1997 and 31 October 2003. The Institutional Review Boards at both institutions approved the study protocol.
To identify the clinical variables associated with SIP, VLBW infants with SIP were identified and their exposure to clinical risk factors determined. Using a case-control design, the incidence of exposure of the patients with SIP to these risk factors was then compared to that of a group of VLBW infants without SIP, allowing for calculation of odds ratios for SIP.
Cases were identified by querying the Neonatal Intensive Care Unit Database for all bowel perforation cases at the two sites. Inclusion criteria consisted of a birth weight of <1500 g and delivery at the study sites during the study period. Patients were excluded if they were diagnosed with NEC as per the attending neonatologist's documented assessment based on clinical, laboratory and radiographic results. Furthermore, patients were also excluded if they were diagnosed with Hirschsprung's disease, meconium ileus, intestinal anomalies, malrotation/volvulus or gastric perforation. Finally, as the majority of cases with SIP present within the first 14 postnatal days, 7, 23 patients diagnosed with SIP after 14 days of postnatal life were also excluded. Two controls were matched by birth weight for each case from the same study site. The two controls matched must have had their birth weight within 100 g of the birth weight of the given patient with SIP. To allow for the inclusion of as many clinically relevant variables as possible in the data analysis, matching was not extended to other variables. The sample size was determined by all patients that could be enrolled based on the inclusion and exclusion criteria.
Data recorded for each subject included the study site, gestational age, birth weight, growth classification (small for gestational age (SGA), appropriate for gestational age (AGA) or large for gestational age (LGA)), administration of a complete course of antenatal steroids (defined as two doses of betamethasone or four doses dexamethasone), maternal conditions (pregnancyinduced hypertension (PIH), pre-eclampsia, oligohydramnios, polyhydramnios, placenta previa and placental abruption), maternal substance use, multiple gestation, gender, Apgar scores, mode of ventilatory support, presence of pulmonary air leak, position of the umbilical arterial line (high: T6-T9 or low: L3-L4), presence of stool before indomethacin or corticosteroids and before perforation, use of oral contrast, enemas (saline or contrast) and/or glycerin suppository, highest dose of vasopressor/ inotrope and postnatal age when administered, duration of vasopressor/inotrope administration before perforation, whether vasopressors/inotropes of X15 mcg/kg/min were administered for >72 h, timing of indomethacin and dexamethasone administration and actual doses received, postnatal age at diagnosis of bowel perforation, whether feeds were given before perforation and if so, the type of feeds (sterile water, formula, or breast milk), antibiotics administered before perforation, presence of hypermagnesemia (defined as serum magnesium levels X2.2 mg/dl), whether surgery was performed and if so, timing of surgery and its findings, whether a peritoneal drain was placed and its timing, whether a PDA was demonstrated by an echocardiogram and whether surgical ligation was performed, positive blood/urine/endotracheal-tube aspirate cultures, serum cortisol level before receiving corticosteroids and whether the patient received medications affecting the gastrointestinal system such as metoclopramide, erythromycin, and/or H 2 -blockers.
In the majority of the cases, indication for indomethacin administration was an echocardiographically verified PDA, although a few patients received indomethacin for IVH prophylaxis within 6 h of delivery. Most patients exposed to indomethacin received the medication within 48 h postnatally (one SIP and one control patient received the first indomethacin dose on the third postnatal day, and one control patient received the first dose of indomethacin on postnatal day 5). Indomethacin was given three times at 0.1 mg/kg/dose every 24 h. If the ductus arteriosus remained open, two additional doses were administered every 24 h.
During the study period, low-dose dexamethasone was used at the two sites to treat vasopressor-resistant hypotension. Vasopressorresistant hypotension was defined as mean arterial pressure at or below the 10th percentile of the gestational-and postnatal-age appropriate norms despite receiving 15-20 mcg/kg/min of dopamine with or without dobutamine administration. Dexamethasone was given at an initial dose of 0.1 mg/kg followed by a 2-day tapering course (four doses at 0.05 mg/kg every 12 h). Thus, the cumulative dexamethasone exposure was 0.3 mg/kg over a 3-day period. The course was terminated early if both dopamine Concurrent use of indomethacin and dexamethasone L Paquette et al and dobutamine requirements became <10 mcg/kg/min. Most but not all patients received a complete steroid course.
In the present study, concurrent administration of indomethacin and dexamethasone is defined as exposure to both drugs during the first postnatal week.
Statistical analysis
Distributions of continuous variables were tested for normality. For normally distributed variables, equality of the means was tested by t-test. For all other continuous variables, equality of distribution was tested by the Mann-Whitney test. For categorical variables and continuous variables recorded into ordinal measures, the distribution or proportion of patients between groups was compared by using the Fisher's exact test. Finally, logistic regression analysis was used to investigate the relationship between SIP and a set of clinical risk factors. Analyses were performed with the SAS System, release 9.1, SAS Institute Inc., Cary, NC, USA, and Stata/SE 8.0 (Stata Corporation, College Station, TX, USA).
Results
Sixteen cases were matched by birth weight to 32 controls. Mean birth weight and gestational age did not differ between cases and controls (Table 1 ). There were no differences between the two groups in the maternal and perinatal characteristics tested (Table 2) . Among the clinical characteristics tested, significant differences between the groups included the number of patients with multiple gestation (six patients in the 'Case Group' vs 0 patient in the 'Control Group'; P<0.0001), maximum vasopressor/ inotrope requirement (P ¼ 0.049), and the proportion of PDA ligation (six of 16 in the 'Case Group' vs three out of 32 in the 'Control Group'; P ¼ 0.019) ( Table 1) . Other clinical characteristics including the cumulative doses of indomethacin or dexamethasone were not significantly different between the two groups (Table 1) .
To investigate the relative contribution of each clinical variable to the risk for the development of SIP, univariate logistic regression analysis was performed (Table 3 and Figure 1) . Patients who first passed stool after the third postnatal day were 2.6 times more likely to have SIP than if the first stool occurred earlier (95% CI 1.02, 6.64). Patients who received the first dexamethasone dose during the first postnatal week were 3.8 times As a result of the relatively small sample size of this study, we are unable to comment on the relationship between gestational age and SIP when gestational age is used as a dichotomized variable. Maternal, perinatal and neonatal clinical variables tested but not predictive of SIP by univariate logistic regression analysis, are depicted in Table 4 .
To adjust for clinically relevant confounding variables, multivariate logistic regression analysis was performed. The analysis revealed that after adjusting for gestational age, Apgar scores, umbilical line position, day of first stool, maximum vasopressor/inotrope dose, and cumulative indomethacin and dexamethasone dose, the relative risk for developing SIP is 9.6 for VLBW infants exposed to X3 doses of indomethacin and X3 doses of dexamethasone as compared to infants exposed to less than three doses of indomethacin and dexamethasone (95% CI 1.22, 75.71).
Discussion
The findings of the present study demonstrate that exposure of VLBW neonates to X3 doses of both indomethacin and dexamethasone during the first postnatal week increases their risk for SIP by 9.6-fold. In addition, delayed stooling, dexamethasone exposure during the first postnatal week and the need for PDA ligation are predictive for the development of SIP; while feeding and feeding before the eleventh postnatal day decrease the risk of SIP in this patient population.
The pathogenetic factors of SIP are not well understood. SIP of the ELBW neonate occurs in the distal ileum, which has a precarious blood supply (''watershed area''); therefore, local ischemia is one of the more commonly proposed mechanisms. However, retrospective chart reviews and case reports are the only studies supporting a role of intestinal ischemia in the development of SIP. 2, 7, 12, 14, 30 Our patients with SIP did have a significantly greater need for vasopressor/inotrope support and exposure to high doses of dopamine may have placed them at risk for vasoconstriction in general and intestinal hypoperfusion in particular. On the other hand, their greater need for vasopressor/ inotrope support may have been an indicator of their severe underlying hemodynamic instability, which in itself could increase the risk of bowel ischemia. As our analysis did not reveal a statistically significant odds ratio for dopamine exposure in the development of SIP, it is unlikely that dopamine administration is an independent risk factor for SIP. Other variables potentially associated with intestinal hypoperfusion such as low Apgar scores, umbilical arterial lines, maternal substance use, placenta previa, placental abruption and SGA status were also excluded as independent risk factors for SIP. Therefore, our findings do not support a leading role of generalized intestinal hypoperfusion in the pathogenesis of SIP in the VLBW neonate. Infection has been considered as another possible instigator of SIP. Although retrospective chart reviews and matched casecontrol studies have documented infection before the development of SIP, 2,4,5,13,15,17 another case-control study 19 and the present study could not find an association between infection and SIP. Thus, it is unclear whether infection plays a role in the development of SIP or it is only an indicator of the more severe condition of patients presenting with SIP compared to their cohorts. The process of initiating feeds and the stooling pattern of the VLBW neonate are often riddled with anxiety by the clinicians worrying about the development of gastrointestinal pathology in this patient population. It is accepted that the risk for NEC increases once feeds have been started. However, it is not well understood whether feeds increase the risk of SIP. Retrospective chart reviews and a large case-control study found no increased risk for SIP if the patient had been fed before the perforation. 8, 10, 11, 30 Interestingly, our findings indicate that patients who received feedings were almost 50 times less likely to develop SIP than patients not fed. We also found that patients fed within the first 10 postnatal days were almost 90 times less likely to have an intestinal perforation. No report on stooling patterns as a possible predictor of SIP has been previously published. In this regard, our results suggest that if a baby has not stooled by the third postnatal day, the patient is 2.6 times more likely to develop SIP. However, delayed stooling beyond the third postnatal day was not associated with a greater risk per day for developing SIP. One may speculate that decreased gut motility may be associated with an increased stress on the bowel mucosa as secretions continue to pool, stretching the bowel wall. This then may result in decreased perfusion especially at the watershed areas in the ileum. However, since hypermagnesemia and infection can cause ileus and neither was found to increase the risk of SIP, it remains unclear whether decreased gut motility plays a role in the development of SIP. Finally, it is important to note that, although feeds may be protective, it is also plausible that the sicker patients are less likely to be fed and are at greater risk of perforation. This notion and the observations that patients in our study with SIP were not fed once the diagnosis was made and that babies who have not stooled are not usually fed, invite further caution when interpreting our findings suggesting a protection from SIP with feedings and a normal stooling pattern.
As for the association between SIP and postnatal corticosteroid exposure, most 2,16 -23 but not all 10 studies have found an increased likelihood of SIP when dexamethasone is used early for the prevention or treatment of BPD. At present it is unclear whether early hydrocortisone exposure is associated with an increased risk of SIP as the available findings are contradictory. 16, 25 However, it is important to note that in the RCTs reporting on the association between dexamethasone use and SIP 20, 22 or on the lack of an association between hydrocortisone exposure and SIP, 25 SIP was only a secondary outcome measure. Proposed mechanisms of the increased risk of SIP with dexamethasone exposure include the thinning of the muscularis and thickening of the adjacent mucosa.
2,7,18,21 Other mechanisms include the inhibition of Other statistically nonsignificant categorical and continuous variables tested but not shown in the tables include polyhydramnios, placenta previa, stool before SIP, total days of maximum vasopressor administration, a total of 7-10 doses of dexamethasone, total of >10 doses of dexamethasone, metoclopramide exposure and positive urine culture. Abbreviations: CI, confidence interval; DEXA, dexamethasone; INDO, indomethacin; AGA, appropriate for gestational age;
LGA, large for gestational age; SGA, small for gestational age; UAC, umbilical artery catheter.
Concurrent use of indomethacin and dexamethasone L Paquette et al local prostacyclin and nitric oxide production 32 especially affecting ileal mucosal perfusion in the watershed regions. Thus, corticosteroids have several mechanisms by which ileal mucosal integrity, metabolism and blood flow regulation may be affected, potentially resulting in an increased risk for the development of SIP.
Our findings indicate that there is a significant relationship between early dexamethasone exposure and SIP. Similar to earlier findings, 16, 20, 25 our data also suggest that the timing of dexamethasone administration is important for the development of SIP as steroid administration within the first week was associated with a 3.8 times greater likelihood of SIP compared to steroid exposure after the first postnatal week. Our data also suggest a lack of a dose-related effect of dexamethasone exposure on SIP. With one exception, 20 this observation is supported by the findings of other investigators. 22, 23 In this regard, our finding that baseline serum cortisol levels were not predictive of SIP is important. Taken together, these findings suggest that a 'threshold' serum corticosteroid concentration easily achievable by the administration of relatively low-doses of dexamethasone may be all that is needed to increase the risk of SIP. In addition, exposure to this 'threshold' serum corticosteroid concentration may be most important for the development of SIP at a critical time when developmental molecular changes are intensified in the immediate postnatal period in the immature gut of the VLBW neonate suddenly exposed to the extrauterine milieu.
More controversy exists about the association between indomethacin exposure and SIP. Although several studies have found no increased risk of SIP in VLBW neonates who received indomethacin, 5, 11, 15, 19, 25, 26 a number of other studies did find an association between indomethacin exposure and SIP. 1,2,8,22,28 -31 A recent case-control study including >600 SIP patients also demonstrated a significant association between indomethacin given in the first three postnatal days and the development of SIP. 16 Our findings did not show that indomethacin alone increases the risk of SIP and neither did they demonstrate an increased risk with earlier indomethacin administration. Our patients with SIP did, however, have a greater PDA ligation rate. Therefore, it is tempting to speculate that, in the VLBW neonate with a large PDA unresponsive to indomethacin, the combined hemodynamic and vascular effects of the PDA and indomethacin, respectively, place the patient at a greater risk of SIP. In support of this notion is the finding that the average cumulative dose of indomethacin was less in our patients with SIP than in the controls.
A few studies have provided suggestive evidence for a possible additive or synergistic effect of the combined use of postnatal corticosteroids (dexamethasone or hydrocortisone) and indomethacin on the risk of SIP. 6, 19, 20, 22, 25 However, none of these studies were designed to specifically examine this association. The findings of the present study indicate that a VLBW neonate who receives three or more doses of both indomethacin and low-dose dexamethasone has a 9.6 times greater risk for developing SIP (P ¼ 0.03). As both dexamethasone and indomethacin affect blood supply, barrier function and tissue integrity by several mechanisms in the intestine, these medications may enhance each other's action on the ileum. These actions may result in functional and structural changes 2,7,18,19,21,28 -30,32 and may explain the increased risk for perforations when both corticosteroids and indomethacin are administered.
Limitations of our study include its retrospective nature, the absence of multiple gestation patients in the control group, the small sample size from a single center with a low overall incidence (2%) of SIP and the lack of the availability of pathology specimen findings. As twins may be at an increased risk for SIP, 2 our results may have been more convincing if matching had included multiple gestations in the control group. Strengths of this study include that it was designed to specifically test for the presence of the association between SIP and the combined use of corticosteroids and indomethacin and that it was a 1:2 case-control study covering a 6-year period at a single center with two institutions attended by the same neonatologists. In addition, this is the first study examining the effect of the combination of indomethacin use and dexamenthasone administration for vasopressor-resistant hypotension.
In summary, our findings indicate that exposure to more than three doses of both indomethacin and dexamethasone during the first postnatal week places the VLBW infant at a significantly increased risk of the development of SIP. Therefore, concurrent administration of indomethacin and dexamethasone (or hydrocortisone) should be avoided if possible in the VLBW neonate during this period. Indeed, findings of previous studies lend support to this notion. 6, 19, 20, 22, 25 However, it remains unclear whether the administration of corticosteroids during the second postnatal week to the VLBW neonate exposed to indomethacin during the first postnatal week increases the risk of SIP.
